This content is from: Patents

Pharma turns to trade secrets and open source for software

Counsel at Bayer, Regeneron and two other companies explain what the rise of software in their firms means for IP protection and finding outside counsel

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Related

Instant access to all of our content. Membership Options | 30 Day Trial